NATIONAL HEPATITIS B&C
TRAINING PROGRAM AND TREATMENT UPDATE 2019

Course Overview
The Scripps National Hepatitis B & C Training Program and Treatment Update will contribute towards increasing the number of health care practitioners educated on the prevalence of chronic viral hepatitis, as well as those properly preventing, diagnosing, treating, and/or referring patients with chronic illness therefore contributing towards prevention of new cases, and improving management of already infected patients.

Educational Objectives
After attending this live activity, participants should be able to:

- Discuss the prevalence and incidence of acute and chronic hepatitis B and hepatitis C both in the general US population and in at-risk populations.
- Review the history, epidemiology, demographics, natural history, histology, immunology and pathophysiology of the viral infection.
- Discuss state-of-the-art diagnostic and treatment guidelines for both hepatitis B and C.
- Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with HBV and/or HCV.
- Evaluate the multidisciplinary team approach to care of patients with hepatitis B and C.
- Establish a local network of practitioners for information sharing, referrals, etc.
- Improve the health of patients infected with the HBV and/or HCV virus.

Accreditation
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint provideship of Scripps Health and SC Liver Research Consortium. Scripps Health is accredited by the ACCME to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Credits
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please note: ABIM MOC credits will be awarded to those who successfully complete the requirements outlined in the post-conference evaluation. Credits earned will be reported to the ABIM approximately 60 days post conference. These credits will not appear on your CME certificate from Scripps.

Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit(s)™ issued by organizations accredited by the ACCME. For the purpose of relicensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credit(s)™. The majority of state boards accept AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Nurses should check with their state’s Board of Registered Nursing regarding use of CME credit.

American Academy of Physician Assistants
PAs may claim a maximum of 7 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Commercial Support
This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.

SC Liver Research Consortium (SCLRC) is an organization of physicians specializing in hepatology and gastroenterology clinical research. Our mission is to team research sponsors and our network of over 100 research sites together to provide faster, higher-quality research results compared to the “conventional” sponsor-site arrangement. We provide access to our scientific expertise in study design, efficient site selection, streamlined contract and budget negotiations, and management assistance throughout the clinical trial. www.scliver.com
Hepatitis C
We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Birth-cohort screening will be outlined. Tests for HCV, including PCR assays and genotyping, non-invasive testing for fibrosis, interpretations and indications for liver biopsies and the natural history of the disease will all be discussed. We will show how to initiate and monitor patients during treatment with all-oral antiviral treatments for hepatitis C, manage drug-drug interactions and deal with various patient populations including pre- and post-liver transplant, HIV-coinfected and end-stage renal disease patients. We will summarize the latest AASLD/IDSA guidelines using all-oral direct acting antiviral regimens for HCV.

Hepatitis B
We will summarize the history and discovery of HBV infection, discuss the modes of infection and prevalence of disease, and differentiate between acute and chronic infections. We will discuss protective antibodies, vaccination, complications of cirrhosis and hepatocellular carcinoma, tests for HBV, including PCR assays, genotyping and mutation analysis. We will include the latest AASLD guidelines for diagnosis, screening and treatment of chronic hepatitis B using nucleoside and nucleotide analogues for the treatment of chronic HBV including entecavir, TAF (tenofovir alafenamide), pegylated interferons and combinations of these regimens. We will also discuss new curative therapies for HBV in early development.

Faculty Disclosure
In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being part of a the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

A complete listing of disclosures associated with this program can be found on the conference website: [www.scripps.org/hepbc](http://www.scripps.org/hepbc) and in the mobile conference app: [www.grupio.com/HepBC19](http://www.grupio.com/HepBC19)

Registration Policies
**Pre-Registration:**
- Ends Tuesday prior to program date
- **Registration Fee:** $110
**Onsite Registration:**
- Begins Wednesday prior to program date
- **Registration Fee:** $125

Questions?
Scripps Conference Services & CME
858-678-6400

Registration
- Includes: Course tuition, access to online conference materials, internet in meeting space, breakfast, breaks and lunch
- **Does not include:** Travel costs, lodging and parking

Attendance Policies
**Attendee Cancellation, Substitution, Refund**
The course tuition is refundable, minus a $25 processing fee, if your cancellation is received in writing no later than one week prior to the conference date. Attendee substitutions are allowed, but notification must be made in writing within one week of conference date. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to “no shows.”

**Scripps Conference Modification or Cancellation**
Scripps reserves the right to modify the course’s schedule or program as necessary. Scripps also reserves the right to cancel this conference, in which case a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of Scripps cancellation.